« Back to Record
Snauwaert, S., Vanhee, S., Goetgeluk, G., Verstichel, G., van Caeneghem, Y., Velghe, I., Philippé, J., Berneman, Z. N., Plum, J., Taghon, T., Leclercq, G., Thielemans, K. M., Kerre, T., & Vandekerckhove, B. (2012). RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. Haematologica, 97(10), 1539-1547. doi:10.3324/haematol.2012.065581
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/167934



